Resmed Cdi stock
Price history
−6.14% over the period1 year: from $37.76 (November 20, 2025) to $35.44 (November 20, 2026), −6.14%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $35.44 |
| October 30, 2026 | $35.51 |
| September 30, 2026 | $31.98 |
| August 31, 2026 | $33.04 |
| July 31, 2026 | $29.79 |
| June 30, 2026 | $28.88 |
| May 29, 2026 | $28.75 |
| April 30, 2026 | $29.78 |
| March 31, 2026 | $32.16 |
| February 27, 2026 | $36.07 |
| January 30, 2026 | $37.54 |
| December 31, 2025 | $35.94 |
| November 28, 2025 | $39.31 |
| November 20, 2025 | $37.76 |
At a glance
The company
Digital health and cloud-connected medical devices for sleep, breathing health, and residential care software
Latest results
Quarter to September 30, 2026 · EPS $2.92 (estimate $0.27)
TickerLandia's take on Resmed Cdi
- Cheaper than similar companies: trailing 12-month P/E 22 vs 47 (−53%) in a group of 11.
- Strong point: Profitability (87/100 in its group). Weak point: Dividend (28/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−11.27% from the 52-week high
Analysts · 13 analysts
Average target$43.19+21.87% vs. price
Buy 11 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Resmed Cdi
Compared with similar companies: very high profitability.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricelow37
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 18.8 46 P/E (trailing 12 months) 22.3 22 Price/book 2.36 31 EV/EBITDA 9.45 4 Price/sales 8.70 84 Profitabilityvery high87
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 34.0% 94 Net margin 27.8% 94 Gross margin 61.8% 68 ROA 14.8% 91 ROE 26.4% 88 Earnings stabilityaverage56
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.9% 49 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage58
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +10.21% 79 Revenue growth (year over year) +5.90% 50 Earnings growth (year over year) +23.20% 45 Financial strengthhigh80
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.65 79 Debt/equitycounts in reverse: lower means more financial strength 0.10 85 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.31 75 Dividendlow28
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.1% 46 Payout ratio 15.9% 10 Consecutive dividend years 10 years 29 Market momentumstrong71
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +16.61% 80 Relative strength (6 months) +19.77% 81 1-year return −6.14% 39 Distance from 200-day average +12.28% 87 Risklow33
How much the price swings.
Metric Value Position in group Volatility (60 days) 24.2% 17 Maximum drawdown (12 months) 34.3% 50 Beta (1 year) 0.45 30
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Resmed Cdi is cheaper than similar companies
Resmed Cdi's P/E (trailing 12 months): 22.3, −53% against the median of a group of 11 similar companies (47.0).
Compared with 11 similar companies
| Metric | Resmed Cdi | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 22.3 | Low | |
| Forward P/E | 18.8 | Middle | |
| Operating margin | 34.0% | High | |
| ROE | 26.4% | High | |
| Debt/equity | 0.10 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Resmed Cdi. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.41B
Latest quarter · Q3 2026
Net income
$418.41M
Latest quarter · Q3 2026
Quarterly net margin
29.6%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $49.85B
- P/E
- 22.3
- EPS
- $1.59
- Volume
- 1.13M
- Daily trading
- €44.05M
- Dividend yield
- 0.71%
- Last ex-dividend on November 11, 2026
How Resmed Cdi is changing
All resultsRevenue grew 12.1% a year on average over the last 5 years
Operating margin rose from 27.3% to 34.0%
Profits turn into cash: free cash flow equal to 116% of net income
Returns
Resmed Cdi returns with dividends
$1,000 invested in Resmed Cdi 5 years ago, on November 22, 2021, would be worth $1,022 today with dividends reinvested: +2.22% in total, +0.44% per year. On price alone it would be $979 (−2.10%).
| Period | Resmed Cdi | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | +3.63% | −2.54% | $1,036 |
| 6 months | +21.12% | +1.13% | $1,211 |
| Year to date | −1.39% | −1.40% | $986 |
| 1 year | −5.41% | +0.47% | $946 |
| 3 years | +58.31% | +21.74% | $1,583 |
| 5 years | +2.22% | +16.86% | $1,022 |
| 10 years | +382.92% | +60.57% | $4,829 |
Over the last 6 months it has done better than 50% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P/ASX 200: price only. Calculate your investment
The chart in detail
Resmed Cdi: technical analysis
Resmed Cdi shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 21.5% below its all-time closing high ($45.14, August 21, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 58
- Between 30 and 70
- vs 200-session average
- +12.28%
Support and resistance
Price areas where Resmed Cdi has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$38.98+10.00%3 touches, last on February 10, 2026
- Resistance$37.42+5.58%3 touches, last on October 30, 2026
- Resistance$35.46+0.06%2 touches, last on February 25, 2026
- Last price$35.44
- Support$33.33−5.96%3 touches, last on August 31, 2026
- Support$32.51−8.25%2 touches, last on November 3, 2026
- Support$31.68−10.62%2 touches, last on July 7, 2026
Volatility and risk
Over the last year it has moved less than the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 0.45
- Volatility (60 sessions, annualised)
- 24.2%
- Largest fall in the last year
- −34.27%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Resmed Cdi: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Resmed Cdi has been August: +3.85% on average, positive in 16 years out of 27. The weakest has been September: −0.77% on average, positive in 11 years out of 27. November, the current month, has been positive in 18 years out of 26 (+3.68% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.48% | +4.08% | 18 of 27 |
| February | +1.80% | −1.36% | 13 of 27 |
| March | +0.59% | +0.19% | 14 of 27 |
| April | +1.26% | +1.55% | 19 of 27 |
| May | −0.32% | +2.03% | 16 of 27 |
| June | +2.13% | +2.22% | 18 of 27 |
| July | +3.20% | +2.68% | 19 of 27 |
| August | +3.85% | +4.03% | 16 of 27 |
| September | −0.77% | −0.53% | 11 of 27 |
| October | +0.67% | +0.52% | 14 of 27 |
| November | +3.68% | +3.10% | 18 of 26 |
| December | +0.15% | −0.93% | 11 of 27 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Resmed Cdi and its competitors
Employing 11,370 people, ResMed works in digital health and cloud-connected medical devices in the United States and abroad. Its devices cover sleep apnea diagnosis, with the ApneaLink Air portable tester, the NightOwl disposable device and the EasyCare Tx sleep lab solution, while therapy support comes through the AirView remote monitoring system and the myAir patient application. A separate software business serves home medical equipment and pharmacy providers through Brightree, home health and hospice agencies through HEALTHCAREfirst, and skilled nursing and senior living providers through MatrixCare and MEDIFOX DAN.
- Headquarters
- San Diego, United States
- Employees
- 11,370
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Resmed CdiRMD | $33.23B | 34.0% | 22.3 | +21.12% |
| HOYA7741 | $47.84B | 34.4% | 27.3 | −13.64% |
| Fisher And Paykel Healthcare CorpoFPH | $15.85B | 27.6% | 57.7 | +47.73% |
| Lenskart SolutionsLENSKART | $13.82B | 10.5% | 163.9 | +51.79% |
| AnsellANN | $4.31B | 15.0% | 21.6 | +79.76% |
| ResMedRMD | $33.14B | 34.0% | 21.5 | +12.28% |
Same industry or related industries, similar size. Compare Resmed Cdi with its competitors · Full profile
